# TGTX — TG Therapeutics · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** TGTX  
**Sources:** 30  
**Published:** 2026-11-10  
**Canonical:** https://app.k3vl4r.com/research/deep-research-tgtx-tg-therapeutics-catalysts-narrative-risks-5954

---

## Overview

TG Therapeutics (NASDAQ: TGTX) is a commercial-stage biotechnology company headquartered in Morrisville, NC, focused on B-cell mediated diseases, anchored by BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS) [[7]](https://www.marketscreener.com/news/earnings-flash-tgtx-tg-therapeutics-inc-reports-q3-revenue-259-9m-vs-factset-est-of-245-5m-ce785fd3dd88f027), [[18]](https://www.marketwatch.com/investing/stock/tgtx), [[23]](https://ir.tgtherapeutics.com/), [[26]](https://biotechreporter.news/tg-therapeutics-nasdaqtgtx-presents-briumvi-data-at-aan-2026/). As of the latest snapshot it carries a market capitalization of roughly $9 billion [[16]](https://finance.yahoo.com/quote/TGTX/), [[19]](https://stockanalysis.com/stocks/tgtx/), [[20]](https://247wallst.com/companies/tgtx/) and, per the background universe file, is classified as a biotech on NASDAQ.

## Recent catalysts (roughly August–November 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-tgtx-tg-therapeutics-catalysts-narrative-risks-5954 (free to sign up)._